Basilea Pharmaceutica (BSLN) AI Stock Analysis

• Market Cap: CHF650.54M
• Dividend Yield: N/A
• Average Volume (3M): 41.01K
• Price to Earnings (P/E): 16.7
• Beta (1Y): 0.99
• Revenue Growth: 58.51%
• EPS Growth: N/A
• Country: CH
• Employees: 164
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.64
• Shares Outstanding: 13,320,282
• 10 Day Avg. Volume: 32,790
• 30 Day Avg. Volume: 41,007
• PEG Ratio: -0.34
• Price to Book (P/B): 5.22
• Price to Sales (P/S): 2.88
• P/FCF Ratio: 11.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF87.00
• Price Target Upside: 62.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: CHF59.00 ▲(10.49% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is driven primarily by strong financial performance (high margins, accelerating revenue, and solid cash generation) and a constructive earnings outlook with improving balance-sheet position and identifiable pipeline catalysts. These positives are tempered by weak near-term technical momentum and medium-term risks flagged on the call (loss of exclusivity timing, higher R&D spend, and partner/clinical execution uncertainty), while valuation appears reasonable rather than deeply discounted.

Positive Factors

Strong cash generation

Consistent operating and free cash flow levels provide durable internal funding for operations and clinical programs, reducing near-term financing needs. Strong cash balances and positive cash conversion enhance financial flexibility to fund Phase III studies and commercialization over the next several years.

High gross margins & accelerating revenue

Sustained high gross margins combined with renewed revenue growth indicate a structurally profitable product mix (notably Cresemba). This margin profile supports reinvestment capacity and improves resilience to cost increases, underpinning medium-term operating profitability if commercial trends continue.

Substantial non-dilutive R&D funding

Large non-dilutive funding materially lowers the capital burden of late-stage trials and reduces dilution risk. Committed and available grants provide durable financing tailwinds for Phase III programs, improving the probability management can advance pipeline without equity raises.

Negative Factors

Loss of exclusivity risk for Cresemba

Cresemba is a major cash engine; anticipated generic entry within 2–3 years creates structural revenue pressure. Management will need successful Phase III outcomes and commercialization of pipeline assets to replace cash flow, making future growth contingent on execution and new product launches.

Rising R&D investment pressure

Material step-up in R&D spending to run multiple late‑stage trials raises steady-state cash burn and increases reliance on trial success. If programs delay or require additional studies, funding needs and near‑term profitability may be strained, pressuring resources until new approvals generate revenue.

Profitability volatility and remaining debt

Wide margin fluctuations and nontrivial outstanding debt signal earnings sensitivity to milestone timing, product mix and one-offs. Although leverage improved, the absolute debt load and margin volatility reduce runway certainty and constrain strategic optionality if clinical or commercial setbacks occur.

Basilea Pharmaceutica Business Overview & Revenue Model

Company Description

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Basilea Pharmaceutica generates revenue primarily through the commercialization of its pharmaceutical products, including sales of its approved drugs and potential royalties from product licensing agreements. The company also engages in strategic partnerships with larger pharmaceutical firms, which may include upfront payments, milestone payments, and royalties based on future sales. These partnerships are crucial for the development and market access of Basilea's products, especially in international markets. Additionally, the company may receive grants and funding for research and development initiatives, contributing to its overall revenue. Basilea's ability to successfully navigate regulatory approvals and market its products effectively is key to its financial performance.

Basilea Pharmaceutica Financial Statement Overview

Summary

Strong recent fundamentals supported by high gross margins (~81–83%), accelerating revenue growth in 2025 (+26.1% YoY), and robust operating/free cash flow (OCF CHF 62.1m; FCF CHF 59.5m). Offsetting this is notable profitability/capital-structure volatility (net margin swing from 37.2% in 2024 to 17.3% in 2025) and remaining meaningful debt despite improved leverage and positive equity.

Income Statement

Profitability and growth improved meaningfully versus the earlier loss-making years. Revenue accelerated strongly in 2025 (+26.1% YoY) after a flat 2024 (+0.3%), with consistently high gross margins (~81–83%). The main watch-out is earnings volatility: net margin swung from a very strong 37.2% in 2024 to 17.3% in 2025, and margins were much lower earlier in the cycle—suggesting results can be sensitive to mix, milestones, or one-offs.

Balance Sheet

The balance sheet has de-risked materially: shareholder equity moved from negative in 2020–2023 to positive in 2024–2025, and leverage improved with debt-to-equity falling from 1.38x (2024) to 0.79x (2025). However, absolute debt remains sizable (~101M in 2025), and the rapid shift in equity base (and very high return on equity in 2024) signals capital structure and profitability have been volatile, which is a key risk factor for a biotech.

Cash Flow

Cash generation is a clear strength recently. Operating cash flow is solid (62.1M in 2025; 74.4M in 2024) and exceeds net income in both years (about 1.26x in 2025 and 1.63x in 2024), indicating good earnings quality. Free cash flow is also strong (59.5M in 2025; 72.7M in 2024) and closely tracks net income, though free cash flow declined in 2025 (-10.7% YoY), showing some near-term variability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	232.40M	208.54M	157.63M	147.76M	148.12M
Gross Profit	193.10M	169.86M	130.84M	120.96M	124.05M
EBITDA	51.60M	63.13M	23.18M	26.21M	6.72M
Net Income	40.20M	77.59M	10.45M	12.15M	-6.83M
Balance Sheet
Total Assets	282.00M	257.76M	173.29M	220.85M	247.27M
Cash, Cash Equivalents and Short-Term Investments	162.34M	120.71M	59.90M	84.70M	148.70M
Total Debt	100.93M	111.67M	128.61M	187.14M	218.96M
Total Liabilities	154.06M	176.76M	183.29M	241.56M	305.87M
Stockholders Equity	127.94M	81.00M	-10.00M	-20.71M	-58.61M
Cash Flow
Free Cash Flow	59.47M	72.65M	13.21M	3.75M	-32.88M
Operating Cash Flow	62.09M	74.36M	14.24M	7.06M	-32.02M
Investing Cash Flow	-2.86M	-1.01M	-1.03M	91.65M	3.58M
Financing Cash Flow	-21.43M	-13.16M	-57.30M	-45.25M	16.64M

Basilea Pharmaceutica Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BSLN, the sentiment is Neutral. The current price of 53.4 is below the 20-day moving average (MA) of 55.78, below the 50-day MA of 54.85, and above the 200-day MA of 50.06, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 43.03 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:BSLN.

Basilea Pharmaceutica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	71 Outperform	CHF650.54M	16.74	―	―	58.51%	―
NWRN	67 Neutral	$378.28M	16.03	―	―	744.64%	―
KURN	61 Neutral	CHF1.04B	-165.93	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	48 Neutral	CHF157.46M	-2.31	-49.86%	―	-100.00%	14.45%
SANN	48 Neutral	CHF224.42M	-3.16	-301.13%	―	-56.85%	-186.55%
IDIA	46 Neutral	CHF906.65M	-5.61	―	―	229.23%	63.47%

Basilea Pharmaceutica Corporate Events

Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs

Basilea Pharmaceutica has secured USD 6 million in funding from the U.S. Biomedical Advanced Research and Development Authority to advance its novel oral antibiotic combination Ceftibuten-Ledaborbactam Etzadroxil for complicated urinary tract infections, including kidney infections. Under the existing contract, Basilea may receive up to an additional USD 147 million in non-dilutive funding as it progresses toward Phase 3 trials, positioning the candidate as a potential first oral beta-lactam/beta-lactamase inhibitor option against multidrug-resistant Enterobacterales and addressing a major gap in cUTI treatment options.

The drug pairs the approved cephalosporin Ceftibuten with the novel beta-lactamase inhibitor Ledaborbactam Etzadroxil, which has shown the ability in preclinical studies to restore antibiotic activity against ESBL-, cephalosporinase- and carbapenemase-producing gram-negative bacteria. Ceftibuten-Ledaborbactam Etzadroxil, designated as a Qualified Infectious Disease Product with Fast Track status by the FDA for complicated and uncomplicated urinary tract infections, remains investigational but could strengthen Basilea’s position in the anti-infectives market if successfully developed and approved.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF69.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.

Basilea boosts revenues, triples net cash as anti‑infective pipeline advances

Basilea Pharmaceutica reported 2025 total revenue of CHF 232.4 million, up 11.4%, driven by a 15.4% rise in license income and strong demand for Cresemba, alongside higher BARDA‑ and CARB‑X‑related contract revenues. Despite increased R&D spending on Phase 3 programs for Fosmanogepix and preparations for Ceftibuten‑Ledaborbactam, the company remained profitable with CHF 51.5 million in operating profit, tripled its net cash position to CHF 86.9 million, and further reduced convertible debt.

Management framed 2025 as a springboard for a new growth phase, underpinned by an expected CHF 600 million in cumulative cash flows from Cresemba and Zevtera over five years and plans to have four anti‑infective drugs on the market by 2030. For 2026, Basilea guides to around 10% total revenue growth and a 20% increase in operating profit, signaling confidence that its strengthened balance sheet and advancing late‑stage pipeline will support both continued deleveraging and investment in external growth opportunities.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF62.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.